Lipidomic and metabolic changes in the P4-type ATPase ATP10D deficient C57BL/6J wild type mice upon rescue of ATP10D function by Sigrüner, Alexander et al.
RESEARCH ARTICLE
Lipidomic and metabolic changes in the P4-
type ATPase ATP10D deficient C57BL/6J wild
type mice upon rescue of ATP10D function
Alexander Sigruener1*, Christian Wolfrum2, Alfred Boettcher1, Thomas Kopf1,
Gerhard Liebisch1, Evelyn Orso´1, Gerd Schmitz1
1 Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Medical Center,
Regensburg, Germany, 2 Institute of Molecular Systems Biology, ETH Zu¨rich, Zu¨rich, Switzerland
* alexander.sigruener@ukr.de
Abstract
Background
Sequence variants near the human gene for P4-type ATPase, class V, type 10D (ATP10D)
were shown to significantly associate with circulating hexosylceramide d18:1/16:0 and
d18:1/24:1 levels, obesity, insulin resistance, plasma high density lipoprotein (HDL), coro-
nary stenotic index and intracranial atherosclerotic index. In mice Atp10d is associated with
HDL modulation and C57BL/6 mice expressing a truncated, non-functional form of ATP10D
easily develop obesity and insulin resistance on high-fat diet.
Results
We analyzed metabolic differences of ATP10D deficient C57BL/6J wild type and ATP10D
transgenic C57BL/6J BAC129 mice. ATP10D transgenic mice gain 25% less weight on
high-fat diet concomitant with a reduced increase in fat cell mass but independent of adipo-
cyte size change. ATP10D transgenic mice also had 26% lower triacylglycerol levels with
approximately 76% bound to very low density lipoprotein while in ATP10D deficient wild
type mice 57% are bound to low density lipoprotein. Furthermore increased oxygen con-
sumption and CO2 production, 38% lower glucose and 69% lower insulin levels and better
insulin sensitivity were observed in ATP10D transgenic mice. Besides decreased hexosyl-
ceramide species levels were detected. Part of these effects may be due to reduced hepatic
stearoyl-CoA desaturase 1 (SCD1) expression in ATP10D transgenic mice, which was
reflected by altered fatty acid and lipid species patterns. There was a significant decrease in
the hepatic 18:1 to 18:0 free fatty acid ratio in transgenic mice. The ratio of 16:1 to 16:0 was
not significantly different. Interestingly both ratios were significantly reduced in plasma total
fatty acids.
Summary
In summary we found that ATP10D reduces high-fat diet induced obesity and improves
insulin sensitivity. ATP10D transgenic mice showed altered hepatic expression of lipid-
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metabolism associated genes, including Scd1, along with changes in hepatic and plasma
lipid species and plasma lipoprotein pattern.
Introduction
Insulin resistance (IR) is a major constituent of the metabolic syndrome predisposing to type 2
diabetes (T2D) mellitus and cardiovascular complications which both still cause approximately
50% of all deaths in Europe [1]. Even though IR is well studied, the factors leading to the pro-
gression of this disease have only been poorly defined. In recent years it has become evident
that certain lipid molecular species can cause IR. Especially glucosylceramides have been
reported to be involved in the progression of IR and T2D [2]. In the EUROSPAN study, a
human genome-wide association between clinical and laboratory phenotypes and single-
nucleotide polymorphisms (SNPs), we successfully identified SNPs in serine palmitoyltransfer-
ase, long chain base subunit 3, ceramide synthase 4, sphingosine-1-phosphate phosphatase 1,
the fatty acid desaturases 1–3 and ATPase, class V, type 10D (ATP10D) that associated with
plasma levels of certain sphingolipid species. SNPs in the region of the P4 ATPase family gene
ATP10D showed significant associations with circulating hexosylceramide (HexCer) d18:1/
16:0 and d18:1/24:1 (mainly glucosylceramide [3]) and myocardial infarction [4]. Recently,
one of these SNPs, rs2351791, was also shown to be associated with plasma high density lipo-
protein (HDL), coronary stenotic index and intracranial atherosclerotic index [5].
The P4 ATPase family consists of multispan transmembrane translocases involved in phos-
pholipid transfer from the exoplasmic/luminal side to the cytoplasmic membrane leaflet [6].
The importance of P4 ATPases for maintenance of membrane asymmetry is underlined by
ATPase, aminophospholipid transporter, class I, type 8B, member 1 (ATP8B1). Mutations in
the human ATP8B1 gene lead to Progressive Familial Cholestasis type 1 and Benign Recurrent
Intrahepatic Cholestasis type 1 [7]. Subcellular localization of P4 ATPases depends on interac-
tion with members of the CDC50 family, representing accessory β-subunits for membrane
translocation that may also determine substrate specificity [8]. Recently, it was shown that the
P4 ATPase ATP10D in a transmembrane protein 30A (TMEM30A/CDC50A) dependent
manner translocates from the endoplasmatic reticulum to the plasma membrane [9].
In mice Atp10d is located in a genomic region associated to HDL modulation [10,11]. Inter-
estingly, C57BL/6 mice that express a truncated, non-functional ATP10D protein due to a
nonsense mutation [12] are one of the most susceptible strains to develop IR and T2D when
exposed to a high-fat diet (HFD) [13]. In this study we analyzed the role of ATP10D in the pro-
gression of IR and metabolic homeostasis through the generation of a novel transgenic mouse
model in which we rescued the aberrant Atp10d expression.
Material and methods
Generation of C57BL/6J transgenic BAC129 Atp10d mice
Heterozygous C57BL/6J transgenic BAC129 Atp10d mice (TG) were generated by pronuclear
injection of a bacterial artificial chromosome BAC containing the Sv129 full length Atp10d
(BAC number BmQ383-E5). Integration of BAC and copy number were determined by qPCR.
All animal experiments were approved by the Kantonale Tierversuchskommission des Kan-
tons Zu¨rich (Permit number 135).
All animal were maintained in C57BL/6J background and maintained on a 12 hours light/
dark cycle in a pathogen-free animal facility. Groups of animals were fed a high fat diet (Kliba)
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containing 60% fat for the indicated times. After 8 weeks and fasting overnight loss of con-
sciousness was produced by rising concentrations of CO2. Mice were then exsanguinated by
cardiac puncture and heart perfused with 0.9% NaCl before liver, visceral adipose tissue, sub-
cutaneous adipose tissue, brown adipose tissue, spleen and heart were collected.
Metabolic cage analysis
Measurements of food and water intake and O2 consumption / CO2 production is performed
non-invasively using an automatic feeding monitoring system coupled to an open-circuit indi-
rect calorimetry system (TSE Phenomaster System). In addition, via infrared light-beam
frames detailed measurements of spontaneous home cage activity can be obtained. Mice are
single housed in regular type III cages; food and water are available ad libitum and intake can
be constantly monitored. Food intake was not altered between the two lines (data not shown).
Each cage is connected to the fresh air supply as well as the sample switch unit for drawing air
samples from each cage. Cages (n = 12) are enclosed in a ventilated cabinet (TSE Systems) to
precisely control ambient temperature and light intensity.
Insulin tolerance test
The intraperitoneal insulin tolerance test (ITT) measures glucose levels subsequent to a stan-
dardized insulin load. It gives an estimate of the insulin sensitivity (IS) of the animals. Animals
are fasted for 14 to 16 hrs, afterwards a bolus of insulin is administered intraperitoneally (IP,
1U/kg BW). Blood is withdrawn by tail vein incision at different time points, and glucose is
measured.
Genomic DNA extraction and Atp10d Exon 12 amplification
DNA was isolated from 20 mg of liver using the QIAamp DNA Mini Kit (Qiagen). Quantity
und purity were measured with Nanodrop (PeqLab). Atp10d exon 12 was amplified using the
following oligonucleotides: FWD: TCA CGT GTA GCG TCG TTT TC, REV: CTG ACC ATC
ACC ATG GCA AC.
Lipoprotein separation by Fast Phase Liquid Chromatography
Plasma lipoprotein fractions were isolated by Fast Phase Liquid Chromatography as previously
published [14]. Cholesterol and triglycerides in the fractions were determined with commer-
cial kits (Roche) on the Cobas Integra 400 plus.
Native gradient gel electrophoresis
6 μl of plasma were stained with 2 μl (0.1 mg/ml in dimethyl sulfoxide) lipophilic dialkylami-
nostyryl fluorophore (Di10-ASP-PS, Molecular Probes) and diluted with 8 μl 2x native sample
buffer (Invitrogen). 5 μl of the sample were separated by 4 to 16% polyacrylamide gradient gel
electrophoresis in native running buffer (Invitrogen) at 60 V for 18 h at 10˚C. In addition, five
reference proteins (HMW-Native Marker Kit, GE-Healthcare) were run simultaneously for
calibrating particle sizes: thyroglobulin (17 nm), apoferritin (12.2 nm), catalase (9.2 nm), lacta-
tedehydrogenase (8.2 nm), and BSA (7.1 nm). LDL particles were determined by comparing
migration distances to those of proteins of known size [15]. PAGE-gels were scanned on a
Typhoon 9400 scanner (GE Healthcare) with an excitation of 488 nm and emission of 610 nm
to detect the fluorescence dye bound to the serum lipoproteins.
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RNA extraction
10 mg frozen liver were thawed in RLT buffer containing beta-mercaptoethanol and homoge-
nized using a Precelly 24 (PeqLab; 5000 rpm, 20 sec). After centrifugation (2000 rpm, 10 min)
RNA was isolated using the RNeasy tissue mini kit and DNA digestion was performed on col-
umn (Qiagen). RNA quality was assessed with Bioanalyzer 2100 (Agilent). Quantity und purity
were measured with Nanodrop (PeqLab).
Micro array and pathway analysis
200 ng of total RNA were processed with the One-Color Quick Amp Labeling Kit according to
the manufacturer’s instructions (Agilent). cRNA quantity and labeling efficiency was checked
with Nanodrop (PeqLab). Scanning of arrays was performed with the G2565CA (Agilent)
(5μM, single pass, 20 bit, no XDR). Micro array scan data were extracted with Feature Extrac-
tion software 10.7.3.1 (Agilent). After elimination of noise and flagged signals data were ana-
lyzed with ChipInspector (Genomatix). Gene regulated more than 2 fold with a mean signal
bigger 100 in at least one of the groups were considered for further analysis.
TaqMan PCR
TaqMan PCR assays were performed on the ABI Prism 7900 HT Sequence Detection System
(Life Technologies) using commercial assays (Life Technologies: 18s rRNA–Hs99999901_s1,
Agpat9—Mm04211965_m1, Atp10d - Mm00462762_m1, Cidec—Mm00617672_m1, Fgf21—
Mm00840165_g1, Lpin1—Mm00550511_m1, Scd1—Mm01197142_m1, Srebf1—
Mm00550338_m1). Relative quantification was carried out as described earlier [16].
Atp10d Exon 12 qPCR
10 ng of liver cDNA were amplified using the following oligonucleotides: FWD: GGC TTC CAA
CCT GTG CTA TG, REV: TGA CCA CGA CCG ACA TTC TT.
Atp10d Exon 12 Sanger sequencing
The relevant position was directly sequenced on both strands by the Sanger method (genomic:
FWD: GTG CTA TGA GGC GGA GAG AGT C, REV: CTG ACC ATC ACC ATG GCA AC; RNA:
amplification oligonucleotides). The sequencing reaction was performed with the BigDye Ter-
minator v1.1 Cycle Sequencing Kit (Life Technologies), purified with the DyeEx 2.0 Spin Kit
(Qiagen) and analyzed on a ABI Prism 3130xl (Life Technologies) capillary sequencer.
Adipocyte size quantification
Adipocyte size was quantified using hematoxylin and eosin stained sections coupled to an
automated image analysis using the Cell Profiler Pipeline as described previously [17].
Protein isolation and immunoblot
Liver tissues (20–30 mg) were homogenized in RIPA buffer (150 mM NaCL, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with protease inhibitors.
The extracts were incubated on ice for 20 minutes and then centrifuged at 15,000 g 15 min to
remove tissue debris. Protein concentrations were determined by bicinchoninic acid assay
(Pierce) and 15 μg of lysates were subjected to SDS-polyacrylamide gel electrophoresis on
4–12% Bis-Tris polyacrylamide gels with MOPS running buffer (Invitrogen). Proteins were
transferred onto polyvinylidene difluoride-membranes (BioRad) which were then blocked by
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incubation for 1 h with 5% nonfat dry milk in PBS. Primary antibodies (anti-SCD1 (C12H5)
Rabbit-mAb (Cell Signaling: 2794), anti-FGF21 (EPR8314) Rabbit-mAb (abcam: ab171941) or
anti-ß-actin (AC-74) mouse monoclonal (Sigma: A5316)) were diluted in 1% nonfat dry milk
in PBS with 0.1% Tween 20 and interacting anti-rabbit-or anti-mouse-horseradish peroxidase-
IgG (Jackson ImmunoResearch) was detected by chemiluminescence ECL-Pus blot detection
system (GE-Healthcare). Quantification was done with ImageJ software [18].
Lipid analysis
1 ml of a 1:1 mixture of water and methanol was added to 50 mg tissue. The samples were
homogenized using a Precelly 24 (PeqLab; 2 x 20 sec 6500rpm, ice 30 sec, 20 sec 6500 rpm).
Hepatic triacylglycerols (TAG) were extracted according Bligh and Dyer [19] and deter-
mined by thin-layer-chromatography. Samples were dried in a SpeedVac and dissolved in
100 μl of 1:1 chloroform / methanol. A high performance thin layer chromatography silica gel
60 (Merck) plate was conditioned for 30 min at 150˚C before applying the samples. The plate
was subsequently developed with three solvent mixtures: First 1:1 ethyl acetate / heptane, fol-
lowed by 50:47.5:2.5 diethyl ether / hexane / acetic acid and finally 3:97 diethyl ether / hexane.
Staining was done with copper(II) sulfate and heating to 150˚C for 30 min. Afterwards the
plate was scanned at 346 nm.
Lipid species were quantified by direct flow injection electrospray ionization tandem mass
spectrometry using the analytical setup and strategy as previously published [20–22]. A precur-
sor ion scan of m/z 184 Da specific for phosphocholine containing lipids was used for phosphati-
dylcholine (PC), lyso-PC (LPC) and sphingomyelin (SM) [21,22]. Ceramide was analyzed using
a fragment ion of m/z 264 Da [20]. Neutral loss fragments were used for the following lipid clas-
ses: Phosphatidylethanolamine (PE) 141 Da, phosphatidylserine 185 Da, phosphatidylglycerol
(PG) 189 Da and phosphatidylinositol 277 Da [23]. PE-based plasmalogens were analyzed ac-
cording to the principles described by Zemski-Berry [24]. Free cholesterol and cholesteryl ester
(CE) were quantified using a fragment ion of m/z 369 Da after selective derivatization of free
cholesterol [25]. For each lipid class two non-naturally occurring internal standards were added
and quantification was achieved by calibration lines generated by addition of naturally occurring
lipid species to plasma. Liquid chromatography coupled to tandem mass spectrometry was used
to quantify HexCer, lactosylceramides, sphingoid bases, sphingosylphosphorylcholine [26], lyso-
phospholipids sphingosine-1-phosphate and lysophosphatidic acid [27] as well as cardiolipin,
bis(monoacylglycero)phosphate, PG and phosphatidic acid [28].
Deisotoping and data analysis for all lipid classes was performed by self programmedself-
programmed Excel Macros according to the principles described previously [22]. Lipid species
were annotated according to the “Shorthand Notation for Lipid Structures Derived from Mass
Spectrometry” [29]. Glycerophospholipid species were annotated based on assumption of even
numbered carbon chains only. SM species annotation is based on the assumption that d18:1
(dihydroxy 18:1 sphingosine) is the main base.
Total and non-esterified fatty acids were determined by gas chromatography/mass spec-
trometry as previously described [30,31].
Statistical methods
Statistical analyses were performed using the Student´s t-test.
Principal component analysis (PCA)
PCA analysis was performed using the Excel add-in Multibase package (Numerical Dynamics,
Japan).
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Results
Generation of Atp10d transgenic animals
To get more insight into the role of ATP10D a transgenic mouse model was created on the
background of the commonly used C57BL/6J laboratory strain that was previously shown to
express no functional ATP10D [12]. Sequencing of exon 12 of Atp10d confirmed presence of
the functional C-allele (NM_153389.3; c.2448) in hepatic genomic DNA and RNA of Atp10d
transgenic C57BL/6J mice (S1 Fig).
Metabolic effects of ATP10D in HFD
At baseline 6 weeks old male CTRL-mice and TG-mice had similar body weight (CTRL: 19.2
±0.7g; TG: 19.0±0.5g). After 8 weeks on HFD the transgenic mice showed a significantly lower
weight gain (44%) than the CTRL-mice (69%) (Fig 1A), concomitant with a lesser increase in
epididymal fat cell mass. Average fat cell size remained unchanged (Fig 1B). No differences in
weight gain and body weight were observed between the two lines when fed a standard chow
diet (data not shown).
Since we observed a significant difference in body and fat weight between both groups after
8 weeks on HFD, metabolic parameters and plasma lipoprotein fractions were analyzed in
more detail. In the TG-mice plasma glucose (38%) and insulin (69%) were significantly de-
creased compared to the CTRL-mice. In agreement with these data TG-mice also revealed bet-
ter IS (Fig 1C). While TAG levels in plasma were significantly decreased by 26% compared
to the CTRL-mice, free fatty acids (FFA) and cholesterol remained unchanged in TG-mice
(Table 1). Interestingly, TG-mice exhibited reduced hepatic FFA and elevated TAG levels
(Table 1), resulting in a significantly (p<0.05) decreased FFA to TAG ratio in liver (CTRL:
0.033±0.006; TG: 0.017±0.003) indicating improved TAG storage. Furthermore, hepatic and
plasma HexCer levels were approximately twofold decreased in TG-mice. O2-consumption
and CO2-production were both increased by 10% in TG-mice (Table 1). No significant differ-
ences in the respiratory exchange ratio and movement were observed between the two groups.
In TG-mice the vast majority (75.8%) of lipoprotein-bound TAG was found in the very low
density lipoprotein (VLDL) fractions and only 15.5% localized in the low density lipoprotein
(LDL) fractions (Fig 2A). In CTRL-mice however, only 30% of TAG were found in the VLDL
fraction, while TAG content of the LDL fractions was at approximately 57% (Fig 2A). The TG-
mice showed a reduced cholesterol content in the LDL fractions compared to CTRL-mice,
indicating either less or cholesterol poorer LDL particles in the TG-mice (Fig 2A). We con-
firmed these changes in LDL levels by native gradient gel electrophoresis with the individual
plasma samples (Fig 2B). Taken together we demonstrate that re-expression of a functional
Atp10d allele in C57BL/6J mice results in reduced susceptibility to weight gain and the devel-
opment of IR. In addition re-expression of a functional allele leads to changes in LDL content
and composition.
Lipid profiling of different tissues
Free cholesterol and individual species of SM, PC, PC ethers, PE, PE-based plasmalogens,
phosphatidylserine, phosphatidylinositol, LPC, ceramide, HexCer, lactosylceramide, lysopho-
sphatidic acid, bis(monoacylglycero)phosphate, cardiolipin, lyso-PG, phosphatidic acid, PG
and CE were measured in liver, visceral adipose tissue, subcutaneous adipose tissue, brown
adipose tissue, spleen and heart (S1 Data).
PCA revealed no clear discrimination of CTRL-mice from the transgenic mice when com-
paring the lipid profiles of visceral adipose tissue, subcutaneous adipose tissue, brown adipose
Lipidomic and metabolic effects of ATP10D in mice
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Fig 1. Metabolic differences in ATP10D deficient and transgenic mice on high fat diet. A. Body weight
gain over eight weeks on high fat diet. B. Epididymal fat mass and adipocyte size after eight weeks on high fat
Lipidomic and metabolic effects of ATP10D in mice
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tissue and heart. In contrast CTRL-mice and transgenic mice were clearly separated by their
hepatic lipid profiles. Besides the liver also in spleen re-expression of ATP10D leads to lipid
profile changes that allow clearly separation of CTRL-mice and transgenic mice (Fig 3). The
contribution of each lipid species is shown in S1 Table.
Transcriptional effects of ATP10D in HFD
Based on the observed alteration in the hepatic lipid profiles and given the key role of the liver
in lipoprotein metabolism we analyzed hepatic mRNA expression of CTRL- and TG-mice in
more detail by Agilent microarrays. 114 genes with significantly different expression were
detected and classified according to MeSH (S2 Table). Among the top ten MeSH-Terms found
were obesity, lipodystrophy, overweight and overnutrition (Table 2) comprising 28 genes (S2
Table). Cell death-inducing DFFA-like effector c (Cidec), fibroblast growth factor 21 (Fgf21),
phosphatidic acid phosphohydrolase lipin 1 (Lpin1), pituitary tumor-transforming 1, renin 1
structural, delta-9-desaturase stearoyl-Coenzyme A desaturase 1 (Scd1) and sterol regulatory
element binding transcription factor 1 (Srebf1) were found in all categories. The significantly
altered expression of 1-acylglycerol-3-phosphate O-acyltransferase 9 (Agpat9), Cidec, Fgf21,
Scd1 and Atp10d was confirmed by TaqMan RT PCR (Fig 4). In accordance with the array
data the expression of Lpin1 was not significantly different in TG-mice (Fig 4). Changed
diet. C. Insulin tolerance of ATP10D deficient and transgenic mice after eight weeks on high fat diet. ATP10D
deficient, solid line; ATP10D transgenic, dashed line. CTRL, ATP10D deficient; TG, ATP10D transgenic;
*p<0.05; ***p<0.001.
https://doi.org/10.1371/journal.pone.0178368.g001
Table 1. Metabolic differences between ATP10D deficient and transgenic mice on high fat diet.
CTRL SD TG SD p value
Metabolic Parameters—Plasma
Glucose [mmol/L] 7.9 0.9 4.9 1.1 0.031
Insulin [ng/mL] 3.6 0.5 1.1 0.5 0.012
TAG [mg/dL] 128.4 13.4 94.6 8.7 0.042
FFA [mmol/L] 1.0 0.1 1.0 0.2 0.084
Cholesterol [mg/dL] 94.6 8.5 83.9 7.9 0.085
Hepatic TAG and FFA [ng/μg tissue]
CTRL SD TG SD p value
FFA 5.6 0.3 4.4 0.3 0.001
TAG 174.7 37.6 255.8 48.0 0.019
Hepatic and plasma d18:1/16:0 + d18:1/24:1 hexosylceramide
CTRL SD TG SD p value
Plasma [μmol/L] 0.77 0.15 0.34 0.04 0.002
Liver [pmol/mg] 8.20 0.94 4.08 0.64 0.00008
Metabolic Parameters—Others
CTRL SD TG SD p value
VO2 [L/kg/h] 4537 189 5028 165 0.024
VCO2 [L/kg/h] 3164 102 3522 89 0.021
RER 0.9 0.1 0.9 0.1 0.523
Movement [AU] 4855 946 4912 938 0.834
Significant differences between both groups are shown in bold and italics. CTRL, ATP10D deficient; SD, standard deviation; TG, ATP10D transgenic; TAG,
triacylglycerols; FFA, free fatty acids; VO2, O2 consumption; VCO2, CO2 production; RER, respiratory exchange ratio, AU, arbitrary units. n = 5.
https://doi.org/10.1371/journal.pone.0178368.t001
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expression of Srebf1 could not be confirmed (Fig 4). Given the key role of Scd1 in fatty acid
metabolism we focused further analysis on Scd1.
Fig 2. Analysis of plasma lipoprotein fractions of ATP10D deficient and transgenic mice on high fat diet. A. Percentage of total triacylglycerol (solid
line) and cholesterol per fraction (dashed line) of Fast Phase Liquid Chromatography isolated plasma lipoprotein in plasma pools of CTRL- and TG-mice. B.
Native gradient gel electrophoresis of the individual plasma samples (n = 5). The LDL region was calculated by comparison with the migration distances of
proteins of known size [15] and serum LDL was detected using a lipophilic fluorescence dye. CTRL, ATP10D deficient; TG, ATP10D transgenic; VLDL, Very
Low Density Lipoprotein; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein.
https://doi.org/10.1371/journal.pone.0178368.g002
Fig 3. Principal component analysis of the lipid profiles of ATP10D deficient and transgenic mice on high fat diet. A. PCA of the hepatic lipid
profiles. Goodness of fit and prediction ability were 67% and 36%. B. PCA of the lipid profiles of spleen. Goodness of fit and prediction ability were 52%
and 38%. Distances between single mice are shown (for details see S1 Table).
https://doi.org/10.1371/journal.pone.0178368.g003
Lipidomic and metabolic effects of ATP10D in mice
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ATP10D alters Scd1 expression and function under HFD
Gene array and TaqMan analysis revealed decreased levels of Scd1 in liver of TG-mice (S2
Table and Fig 4). Decreased expression of SCD1 in liver of TG-mice could also be confirmed
at the protein level (Fig 5). In agreement with mRNA data hepatic FGF21 protein expression
appears slightly higher in TG-mice (Fig 5).
To substantiate if this regulation of SCD1 is of biological relevance we analyzed hepatic and
plasmatic total and FFA composition. Analysis of hepatic and plasma total fatty acids (TFA)
Table 2. MeSH classification of differentially regulated genes between ATP10D deficient and transgenic mice on high fat diet.
MeSH-Term MeSH-Term id(s) p value Genes observed Genes expected
Liver Diseases • C06.552 0.00003 45 27
Obesity • C23.888.144.699.500 0.00009 27 13
Lipodystrophy • C18.452.880.391
• C17.800.849.391
• C18.452.584.625
0.00010 8 1
Overweight • C23.888.144.699 0.00011 27 13
Obesity • C18.654.726.500 0.00017 27 13
Overnutrition • C18.654.726 0.00017 27 13
Connective Tissue • C17.300 0.00024 32 18
Liver Neoplasms • C06.552.697
• C06.301.623
• C04.588.274.623
0.00036 36 21
Skin Diseases,
Metabolic
• C18.452.880
• C17.800.849
0.00047 9 2
Atherosclerosis • C14.907.137.126.307 0.00055 18 8
Obesity associated categories are shown in bold and italics.
https://doi.org/10.1371/journal.pone.0178368.t002
Fig 4. Expression of selected genes in ATP10D deficient and transgenic mice on high fat diet.
Expression was measured by TaqMan real-time PCR and normalized to 18S rRNA. Mean values of CTRL-
and TG-mice are shown relative to CTRL-mouse1 together with the standard deviation (n = 5). ATP10D
deficient, white bars; ATP10D transgenic, grey bars. *p<0.05.
https://doi.org/10.1371/journal.pone.0178368.g004
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revealed a significant relative decrease of palmitate (16:0) and an increase of linoleic acid (18:2
n-6) in TG-mice (Table 3). Furthermore, a significant relative increase of stearate (18:0) and a
decrease of oleate (18:1 n-9) was observed in plasma TFA in TG-mice (Table 3). This effect
was not apparent in hepatic TFA, however it was found in hepatic FFA. In addition, palmitole-
ate (16:1 n-7) was always slightly lower in TG-mice (Table 3). The observed increase of stearate
(18:0) and decrease of oleate (18:1 n-9) together with the slight decrease of palmitoleate (16:1
n-7) suggests the involvement of SCD1, which forms a cis double bond at the delta-9 position
of saturated fatty acyl-CoA substrates like palmitoyl-CoA and stearoyl-CoA. Therefore, we cal-
culated the product/precursor ratio for oleate (18:1 n-9) to stearate (18:0) and palmitoleate
(16:1 n-7) to palmitate (16:0), the main delta-9-desaturase reaction products of Scd1. No sig-
nificant differences were visible when calculating product/precursor ratios of hepatic TFA, but
there was a significant decrease in the oleate (18:1 n-9) to stearate (18:0) FFA ratio of TG-mice
compared to CTRL-mice (Fig 6). The ratio of palmitoleate (16:1 n-7) to palmitate (16:0) was
not significantly different (Fig 6). Interestingly both ratios were significantly elevated in plasma
TFA (Fig 6).
Fig 5. Hepatic protein levels of FGF21 and SCD1 of ATP10D deficient and transgenic mice on high fat
diet. Immunoblot of FGF21, SCD1 and beta-actin in the individual liver samples. Data were quantified using
ImageJ software [18] and are shown relative to β-Actin as housekeeping protein. CTRL, ATP10D deficient;
TG, ATP10D transgenic; *p<0.05.
https://doi.org/10.1371/journal.pone.0178368.g005
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These findings were confirmed in hepatic and plasmatic lipid classes with only one single
fatty acid side chain. Similar 18:1 to 18:0 and 16:1 to 16:0 shifts were observed in CE and LPC.
While all LPC ratios were significantly different only the shift in plasmatic CE16:1 to 16:0
reached statistical significance (Fig 7).
Overall the 18:1 to 18:0 and 16:1 to 16:0 ratios of CE and LPC in liver and plasma were
quite similar to the oleate (18:1 n-9) to stearate (18:0) and palmitoleate (16:1 n-7) to palmitate
(16:0) ratios of TFA and FFA, with a tendency towards decreased ratios in TG-mice.
Discussion
Here we demonstrated that the commonly used C57BL/6J mouse strain, which is deficient for
ATP10D, exhibits a less favorable metabolic pattern compared to transgenic mice re-expressing
Table 3. Relative amounts of total and free fatty acids in ATP10D deficient and transgenic mice on high fat diet.
Hepatic total fatty acids Hepatic free fatty acids Plasma total fatty acids
CTRL TG CTRL TG CTRL TG
mean SD mean SD mean SD mean SD mean SD mean SD
FA14:0 0.5% 0.1% 0.7% 0.1% 1.7% 0.1% 2.2% 0.2% 0.7% 0.1% 0.6% 0.0%
FA16:0 25.3% 0.6% 22.9% 0.9% 26.8% 1.0% 25.8% 0.7% 27.5% 0.8% 23.4% 0.7%
FA18:0 8.6% 0.7% 8.7% 1.1% 11.2% 0.5% 14.5% 1.4% 7.9% 0.2% 10.0% 0.6%
FA16:1-c9 2.8% 0.6% 2.4% 0.7% 5.2% 1.2% 4.1% 1.1% 2.8% 0.5% 1.7% 0.3%
FA18:1-c9 (n-9) 15.7% 1.2% 17.1% 1.1% 17.0% 0.7% 15.3% 0.8% 11.1% 0.3% 10.5% 0.3%
FA18:2-c9,c12 (n-6) 24.0% 1.7% 27.9% 1.2% 24.6% 1.7% 25.3% 1.5% 26.3% 1.5% 29.7% 0.4%
FA20:4-c5,c8,c11,c14 (n-6) 11.6% 1.0% 9.3% 0.9% 5.0% 0.5% 4.4% 0.5% 15.9% 1.1% 16.2% 0.8%
FA22:6-c4,c7,c10,c13,c16,c19 (n-3) 7.0% 0.6% 6.3% 0.6% 2.9% 0.2% 2.7% 0.4% 4.4% 0.2% 4.8% 0.1%
Significant differences are shown in bold. CTRL, ATP10D deficient; FA, fatty acid; SD, standard deviation; TG, ATP10D transgenic. n = 5.
https://doi.org/10.1371/journal.pone.0178368.t003
Fig 6. SCD1 related fatty acid ratios in liver and plasma of ATP10D deficient and transgenic mice on high fat diet. Total and non-esterified fatty
acids were determined by gas chromatography/mass spectrometry. Mean values are shown together with the standard deviation (n = 5). ATP10D
deficient, white bars; ATP10D transgenic, grey bars; TFA, total fatty acids; FFA, free fatty acids. *** p<0.001; *p<0.05.
https://doi.org/10.1371/journal.pone.0178368.g006
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a functional form of Atp10d. No significant differences in body weight of ATP10D deficient and
transgenic mice were observed when fed a standard chow diet. On a high fat diet TG-mice gain
less weight and fat mass and have lower plasma glucose and insulin levels in accordance with
better IS. O2-consumption/CO2-production were found enhanced. In addition they show a
distinctly altered lipoprotein pattern, reduced hepatic and plasma HexCer levels, a decreased
hepatic FFA to TAG ratio and transcriptional changes of obesity associated genes in liver, in-
cluding delta-9 desaturase Scd1. It has to be noted that the re-expression of ATP10D was con-
ferred by transgenic introduction of a BAC containing the Sv129 Atp10d-gene. Analysis of the
Fig 7. SCD1 related ratios of lipid classes with only one single fatty acid side chain in liver and plasma of ATP10D deficient and transgenic
mice on high fat diet. Lipid species were quantified by electrospray ionization tandem mass spectrometry. Mean values are shown together with the
standard deviation (n = 4). ATP10D deficient, white bars; ATP10D transgenic, grey bars. *** p<0.001; * p<0.05.
https://doi.org/10.1371/journal.pone.0178368.g007
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integration revealed a single copy and we did not observe any noteworthy changes in Atp10d
expression. Nevertheless, it is possible that the site of integration or other proteins encoded on
the BAC might contribute to the observed phenotype.
Interestingly from the tissues analyzed here only the lipid profiles of liver and spleen were
altered enough by re-expression of ATP10D to allow clear separation of CTRL-mice and trans-
genic mice by PCA. Part of these effects could be mediated by the observed reduced SCD1
mRNA and protein expression and the resulting decreased SCD1 product to precursor ratios
in ATP10D transgenic mice. The reduced SCD1 expression in transgenic mice is in agreement
with previous data demonstrating downregulation of SCD1 by PUFAs [32,33] and upregula-
tion by insulin, glucose and saturated fatty acids. ATP10D transgenic mice presented a relative
gain of linoleic acid (18:2) and loss of palmitate in total hepatic and plasma fatty acids. In
contrast to SCD1, Lpin1 was shown to be suppressed by insulin [34] and in obese insulin resis-
tant mice [35] and we detected increased hepatic Lpin1 mRNA levels in TG-mice. As it was
previously shown that Scd1 expression is elevated in Lpin1 null mice [35] the lower Scd1
expression in TG-mice may also in part be due to increased Lpin1 expression.
It was also shown that inhibition of SCD1 protects against diet induced obesity, hepatic
steatosis and IR [36] and that higher SCD-activity is associated with higher plasma TAG, simi-
lar to what we observed in our experiments. Interestingly, upregulation of Lpin1 reduces
hepatic TAG secretion [35]. The finding that TG-mice show lower plasma TAG levels and ele-
vated hepatic TAG may therefore be explained by the observed downregulation of SCD1 and
upregulation of Lpin1.
The decreased hepatic FFA to TAG ratio indicates improved TAG metabolism due to ele-
vated synthesis and/or reduced degradation and/or secretion in TG-mice. This may lead to
decreased release of FFA to the circulation and, therefore to reduced uptake in fat tissue which
may explain the observed lesser weight gain in TG-mice. In addition, there may be a link
between the observed changes in TAG association to lipoproteins and the decreased plasma
TAG levels. It is possible that elevated TAG uptake may prevent modifications of lipoproteins
that lead to the formation of LDL-like particles or the prevention of the generation of LDL-like
particles may increase TAG uptake.
Previously SNPs in ATP10D were shown to be associated with levels of circulating HexCer
[4]. Here we could confirm the functional relevance of this finding as TG-mice showed re-
duced hepatic and plasma HexCer levels compared to CTRL-mice. This may be explained by
the observed relative decrease of palmitate (16:0) in TG-mice. Palmitate was shown to increase
serine palmitoyltransferase activity and thereby enhance sphingolipid de novo synthesis in a
variety of cells (reviewed in [37]). The reduced HexCer levels may contribute to the observed
phenotype of TG-mice as different inhibitors of sphingolipid synthesis were shown to improve
IR, hepatic steatosis and prevent diabesity in rodent obesity models (reviewed in [2]).
Our findings are in good agreement with reports demonstrating the role of ATP10A (for-
merly ATP10C), another class 5 P4-type ATPase, in diet-induced obesity, T2D and insulin-
stimulated glucose uptake [38–40]. Like ATP10D, ATP10A depends upon interaction with
TMEM30A/CDC50A to translocate from the endoplasmatic reticulum to the plasma mem-
brane. There ATP10A revealed PC-specific flipping activity which affects cell shape, adhesion
and spreading. However no flippase activity of ATP10D towards PC, phosphatidylserine, PE
or SM was detected [41].
In summary, we show here that rescue of ATP10D function in mice on C57BL/6J back-
ground leads to reduced HFD induced obesity and IR, altered hepatic expression of lipid-
metabolism associated genes, including reduced SCD1 expression and the resulting decreased
SCD1 product to precursor ratios, and distinct changes in the plasma lipoprotein pattern.
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